Burimamide

Burimamide is an antagonist at the H2 and H3 histamine receptors. It is largely inactive as an H2 antagonist at physiological pH,[1] but its H3 affinity is 100x higher. It is a thiourea derivative.

Burimamide
Names
IUPAC name
1-[4-(1H-imidazol-5-yl)butyl]-3-methylthiourea
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
PubChem CID
UNII
InChI
  • InChI=1S/C9H16N4S/c1-10-9(14)12-5-3-2-4-8-6-11-7-13-8/h6-7H,2-5H2,1H3,(H,11,13)(H2,10,12,14) Y
    Key: HXRBAVXGYZUSED-UHFFFAOYSA-N Y
  • InChI=1/C9H16N4S/c1-10-9(14)12-5-3-2-4-8-6-11-7-13-8/h6-7H,2-5H2,1H3,(H,11,13)(H2,10,12,14)
    Key: HXRBAVXGYZUSED-UHFFFAOYAJ
SMILES
  • CNC(=S)NCCCCc1c[nH]cn1
Properties
Chemical formula
 C9H16N4S
Molar mass 212.32 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Y verify (what is YN ?)
Infobox references

Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers.[2] The discovery of burimamide ultimately led to the development of cimetidine (Tagamet).[2]

See also

References
  1. Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. p. 205. ISBN 978-0-19-850346-0.
  2. "Tagamet: Discovery of Histamine H2-receptor Antagonists". National Historic Chemical Landmarks. American Chemical Society. Archived from the original on December 9, 2012. Retrieved June 25, 2012.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.